Iftikhar Khan: What Is the Optimal Antithrombotic Strategy After Left Atrial Appendage Closure?
Iftikhar Khan, Research Writer at Consentic, Peer Reviewer at Asian Journal of Psychiatry, SAGE Open Medical Case Reports, Antimicrobial Resistance and Infection Control, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Thrombosis and Thrombolysis, adding:
“New meta analysis published!
What’s the optimal antithrombotic strategy after left atrial appendage closure?
In the overall analysis, DOACs were associated with lower all-cause mortality, major bleeding, and device-related thrombosis.
The caveat matters: when we restricted the analysis to RCTs alone, none of these benefits reached significance. The signal was driven largely by observational data.
So, a promising direction, not a practice change. Adequately powered randomized trials are still needed.”
Title: Direct oral anticoagulant dose vs dual antiplatelet therapy after left atrial appendage closure in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis
Authors: Umama Alam, Adam Umar Ahmed, Javeria Javed, Amna Khan, Muhammad Ansab, Iftikhar Khan, Shahzaib Rafi, Zonaira Mushahid, Bushra Nawaz, Muhammad Asad Asif, Rakhee Lohana, Shaiza Naseer Khan, Abdul Moiz, Fazeela Bibi, Bilal Aslam
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn RuksakulpiwatÖ‰ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin
-
Aug 10, 2026, 15:47Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria
-
Aug 10, 2026, 15:45Vrushali Lad: What Living With DVT Taught Me About Lifestyle and Movement